search
Back to results

Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Liraglutide
Placebo-liraglutide
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring liraglutide, victoza, GLP-1, kidney, diabetes, renal, diabetic nephropathy

Eligibility Criteria

20 Years - 60 Years (Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed consent obtained before any trial-related activities.
  • Male gender
  • T2DM, diagnosed according to international guidelines
  • Age 20-60 years, both included
  • Body Mass Index (BMI): 20-32 kg/m2, both included
  • Metformin treatment
  • Albumin/creatinine ratio <25 mg/mmol

Exclusion Criteria:

  • Known or suspected allergy to trial product or related products
  • Previous participation in this trial
  • Previous treatment with GLP-1 analogues or DPP-4 inhibitors
  • Current treatment with any antidiabetic drug other than metformin
  • Poorly regulated glycemic control (HbA1c > 8%)
  • Impaired kidney function: estimated GFR < 70ml/min
  • Impaired liver function: liver parameters exceed 2 times upper normal limit
  • Subjects with active malignancy
  • Severe cardiac insufficiency classified according to NYHA III-IV
  • Unstable angina pectoris, acute myocardial infarction (AMI) within the last 12 months
  • Severe, uncontrolled hypertension: sitting blood pressure (BP) > 180/110 mmHg
  • Antihypertensive treatment consisting of more than two different pharmaceutical products
  • Symptoms related to benign prostate hyperplasia
  • Claustrophobia
  • Any metal body implants
  • History of pancreatitis, type 1 diabetes, gastroparesis or multiple endocrine neoplasia syndrome type 2
  • Personal or family history of medullary thyroid carcinoma
  • Any diseases judged by the investigator that could affect the trial
  • Any medication judged by the investigator that could affect the trial

Sites / Locations

  • Aarhus University Hospital, Department of Endocrinology and Diabetes

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Liraglutide

Placebo-liraglutide

Arm Description

1.2 mg liraglutide sc. (single-dose)

Placebo liraglutide sc. (single-dose)

Outcomes

Primary Outcome Measures

Glomerular Filtration Rate (51Cr-EDTA plasma clearance)

Secondary Outcome Measures

Renal Blood Flow (functional magnetic resonance imaging)
Renal electrolyte clearance
Sodium, potassium, calcium, lithium and osmotically active substances.
Excretion of kidney injury markers
Albumin, NGAL, KIM-1, angiotensinogen and 8-OHdG.
Plasma concentrations of various hormones
Angiotensin II, renin, aldosterone, atrial natriuretic peptide, catecholamines.

Full Information

First Posted
August 10, 2012
Last Updated
February 27, 2014
Sponsor
University of Aarhus
Collaborators
Novo Nordisk A/S, University of Copenhagen
search

1. Study Identification

Unique Protocol Identification Number
NCT01664676
Brief Title
Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
Official Title
A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
February 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
Collaborators
Novo Nordisk A/S, University of Copenhagen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Recent studies in rodents show that glucagon-like peptide-1 (GLP-1) analogues protect against diabetic nephropathy. We hypothesise that this is also the case in humans. This study will investigate the short-term effect of liraglutide (GLP-1 analogue) on the kidneys in type 2 diabetic patients. Impact on basic kidney physiological will be determined and kidney injury markers will be measured as surrogate parameters of kidney protection.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
liraglutide, victoza, GLP-1, kidney, diabetes, renal, diabetic nephropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Liraglutide
Arm Type
Experimental
Arm Description
1.2 mg liraglutide sc. (single-dose)
Arm Title
Placebo-liraglutide
Arm Type
Placebo Comparator
Arm Description
Placebo liraglutide sc. (single-dose)
Intervention Type
Drug
Intervention Name(s)
Liraglutide
Other Intervention Name(s)
Victoza
Intervention Type
Drug
Intervention Name(s)
Placebo-liraglutide
Other Intervention Name(s)
Isotonic saline
Primary Outcome Measure Information:
Title
Glomerular Filtration Rate (51Cr-EDTA plasma clearance)
Time Frame
10-15 hours post-dose
Secondary Outcome Measure Information:
Title
Renal Blood Flow (functional magnetic resonance imaging)
Time Frame
15 hours post-dose
Title
Renal electrolyte clearance
Description
Sodium, potassium, calcium, lithium and osmotically active substances.
Time Frame
10-15 hours post-dose
Title
Excretion of kidney injury markers
Description
Albumin, NGAL, KIM-1, angiotensinogen and 8-OHdG.
Time Frame
0-10 hours and 10-15 hours post-dose
Title
Plasma concentrations of various hormones
Description
Angiotensin II, renin, aldosterone, atrial natriuretic peptide, catecholamines.
Time Frame
10-15 hours post-dose

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent obtained before any trial-related activities. Male gender T2DM, diagnosed according to international guidelines Age 20-60 years, both included Body Mass Index (BMI): 20-32 kg/m2, both included Metformin treatment Albumin/creatinine ratio <25 mg/mmol Exclusion Criteria: Known or suspected allergy to trial product or related products Previous participation in this trial Previous treatment with GLP-1 analogues or DPP-4 inhibitors Current treatment with any antidiabetic drug other than metformin Poorly regulated glycemic control (HbA1c > 8%) Impaired kidney function: estimated GFR < 70ml/min Impaired liver function: liver parameters exceed 2 times upper normal limit Subjects with active malignancy Severe cardiac insufficiency classified according to NYHA III-IV Unstable angina pectoris, acute myocardial infarction (AMI) within the last 12 months Severe, uncontrolled hypertension: sitting blood pressure (BP) > 180/110 mmHg Antihypertensive treatment consisting of more than two different pharmaceutical products Symptoms related to benign prostate hyperplasia Claustrophobia Any metal body implants History of pancreatitis, type 1 diabetes, gastroparesis or multiple endocrine neoplasia syndrome type 2 Personal or family history of medullary thyroid carcinoma Any diseases judged by the investigator that could affect the trial Any medication judged by the investigator that could affect the trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jens S Christiansen, Professor
Organizational Affiliation
Aarhus University Hospital, Department of Endocrinology and Diabetes
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aarhus University Hospital, Department of Endocrinology and Diabetes
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients

We'll reach out to this number within 24 hrs